Omalizumab Improves Outcomes in Allergic Asthma Even With Off-Label Dosing - Pulmonology Advisor
Patients with allergic asthma who initiate omalizumab (OMA) experience similar reductions in exacerbations and hospitalizations regardless of whether or not they fall within the criteria of the approved recommended dosing schedule, according to study results presented at the American College of Chest Physicians (CHEST) 2022 Annual Meeting, held from October 16 to 19, 2022, in Nashville, Tennessee. Many patients treated with omalizumab, an anti-IgE antibody approved for patients with moderate-severe allergic asthma, fall outside the approved recommended dosing schedule, which is determined by a patient's body weight and pretreatment serum IgE levels. Researchers therefore examined exacerbation and hospitalization rates of US patients using omalizumab for allergic asthma who fell outside of the approved dosing schedule. The investigators conducted a post hoc analysis of the PROSPERO study, a prospective, real-world, 48-week multicenter study of 801 p...